天花治疗市场－全球产业规模、份额、趋势、机会和预测：按治疗类型、产品类型、最终用户、地区和竞争格局划分，2021-2031年

全球天花治疗市场预计将从 2025 年的 7,512 万美元成长到 2031 年的 9,461 万美元，复合年增长率为 3.92%。

该市场涵盖抗病毒药物和疫苗等医疗措施，旨在预防和治疗正痘病毒感染疾病，包括天花和猴痘。该领域的成长主要受各国政府为降低生物恐怖主义风险而製定的生物防御储备指令以及控制通用感染疾病再次爆发的需要所驱动。这些采购倡议确保了即使在天花根除后，对已通过核准的治疗方法的需求依然存在，疫苗联盟Gavi已达成一项预购协议，将于2024年采购50万剂疫苗以应对区域性疫情爆发，这便证明了这一点。

市场扩张的主要障碍之一是依赖时断时续的政府合同，而非稳定的商业基本客群。对于日常使用量有限的产品而言，维护生产系统的高昂成本会为私人开发商带来财务上的不稳定性。对公共资金週期的依赖意味着，由于政治议程的变化或预算重新分配，收入来源可能会突然减少，这反过来又会使新进业者对投资这一专业製药领域犹豫不决。

市场驱动因素

由于猴痘和正痘病毒感染疾病的反覆爆发，市场需求激增，这极大地推动了医疗物资的供应。各国纷纷将医疗物资的即时供应列为优先事项。推动这一市场成长的因素包括国际组织和各国政府采取快速反应策略，采购治疗药物和疫苗，以限制跨境病毒传播威胁，并将应对措施从理论上的准备转向积极主动的疾病控制。 2024年，猴痘被宣布为国际关注的突发公共卫生事件，加速了采购管道的运转，并迫使各国政府增加储备以备即时。例如，2024年8月，巴伐利亚北欧公司宣布已采购175,420剂MVA-BN疫苗，以支持欧洲卫生紧急反应署（HERA）在非洲进行的危机应变工作。

同时，国家战略生物防御储备的扩充为製药研发公司提供了长期永续性的根本稳定因素。世界各国政府都认识到天花是一种严重的生物武器威胁，并认识到无论当前感染水平如何，都需要维持第二代疫苗和抗病毒药物的储备。这种以安全为导向的做法促成了多年合约的签订，从而保护公司免受商业性波动的影响。例如，美国卫生与公共服务部行使了一项价值1.13亿美元的口服TPOXX疫苗采购选择权，SIGA Technologies公司于2024年7月宣布了这一消息。此外，Emergent BioSolutions公司在2024年7月报告称，该公司已获得一项价值9990万美元的合约修订，将继续向美国国家战略储备供应其ACAM2000疫苗，这凸显了该行业对联邦国防费用的依赖。

市场挑战

对不规律的政府合约的依赖是全球天花治疗市场的主要阻碍因素，造成收入环境不稳定，阻碍了私部门的稳定投资。与受持续患者需求支撑的商业製药产业不同，天花治疗市场严重依赖生物防御储备义务和不规则的采购週期。製造商必须在没有持续销售保障的情况下维持高成本的专业化生产能力和合规性，从而导致「繁荣与萧条」的交替局面：一旦威胁减弱或公共卫生重点发生转变，收入可能会骤然消失。这使得长期策略规划变得复杂。

这种不稳定性因有条件采购而进一步加剧，因为这种采购仅限于紧急情况而非主动资金筹措。这种被动模式导致企业承担维持产能和管理库存的相关风险。例如，联合国儿童基金会曾考虑在2024年进行紧急竞标，以在2025年前采购多达1,200万剂MPOX疫苗，但此次采购明确取决于已确认的需求和可用资金。这个例子表明，依赖无担保的公共资金以及缺乏稳固的商业性消费群如何阻碍市场维持稳定的成长轨迹。

市场趋势

製造业者と规制当局は、医薬品适応症の拡大に再び注力しています。具体的には、従来の生物防卫戦略で除外されてきた特别なリスクグループや儿童集団を対象に含めることで、歴史的な戦略上の大きな空白を埋める取り组みです。この动向には、オルソポックスウイルスに対する広范な保护を确保するため、特に儿童を対象とした规制措置や临床试験の増加が含まれます。これにより、初期の製剤に见られた严重な副作用なしに、より若い被験者层で免疫を诱导する、安全性が高い第三世代ワクチンの导入へと轴足を移しつつあります。主な発展として、世界保健机関（WHO）は2024年11月、1歳以上の儿童向けLC16m8ワクチンの紧急使用许可を核准し、この脆弱な集団を保护するため、日本からコンゴ民主共和国への305万回分のワクチン寄赠を促进したことを报告しました。

生物製药公司正在加速整合其针对疥痘和天花的开发平臺，以利用当前疫情检验双适应症疗法的有效性。透过利用疥痘病例的临床数据，研发人员可以加快频谱正痘抗病毒药物的监管核准流程，而由于天花已被根除，此类药物的测试原本难以进行。这种策略整合将优化研发支出，并使mRNA技术等新型平台能够快速应对新出现的威胁，同时履行各国政府的长期生物防御义务。例如，Moderna公司针对这两种病毒的mRNA-1769候选药物正在进行I/II期临床试验，相关报告发表于2024年9月的《製药技术》杂誌。

目录

第一章概述

第2章调查方法

第三章执行摘要

第四章：客户心声

第五章：全球天花治疗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 治疗方法（抗病毒药物、疫苗接种、支持性治疗）
  • 依产品类型（疫苗、抗病毒药物）
  • 依最终使用者（医院/诊所、门诊中心、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美天花治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲天花治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区天花治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东与非洲天花治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲天花治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球天花治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Bavarian Nordic A/S
• Chimerix, Inc.
• Pfizer Inc.
• Sanofi SA
• GlaxoSmithKline plc
• Novartis AG
• Johnson & Johnson
• SIGA Technologies, Inc.
• BioCryst Pharmaceuticals, Inc.
• Bharat Biotech International Ltd

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Smallpox Treatment Market is projected to expand from USD 75.12 Million in 2025 to USD 94.61 Million by 2031, achieving a compound annual growth rate of 3.92%. This market encompasses medical countermeasures, such as antiviral therapeutics and vaccines, intended to prevent and treat orthopoxvirus infections like variola and mpox. Sector growth is chiefly upheld by government directives for biodefense stockpiling to mitigate bioterrorism risks and the need to control re-emerging zoonotic outbreaks. These procurement initiatives guarantee continued demand for approved treatments despite smallpox eradication, as evidenced by Gavi, the Vaccine Alliance, which secured an advance purchase agreement for 500,000 vaccine doses in 2024 to tackle rising regional outbreaks.

One major obstacle hindering market expansion is the reliance on intermittent government contracts rather than a steady commercial customer base. The substantial expense of preserving manufacturing readiness for products that see limited routine use introduces financial instability for private developers. Relying on public funding cycles means that changes in political agendas or budget reallocations can suddenly diminish revenue sources, thereby deterring new competitors from investing in this specialized pharmaceutical niche.

Market Driver

The market is effectively propelled by surging demand resulting from recurring mpox and orthopoxvirus outbreaks, leading nations to prioritize the immediate acquisition of medical countermeasures. This driving force involves rapid response strategies where international bodies and governments procure therapeutics and vaccines to limit transboundary viral threats, shifting from theoretical readiness to active disease management. The declaration of mpox as a public health emergency in 2024 hastened these procurement channels, forcing authorities to increase inventories for immediate use; for instance, Bavarian Nordic announced in August 2024 that the European Health Emergency Preparedness and Response Authority (HERA) purchased 175,420 doses of the MVA-BN vaccine to aid the response to the crisis in Africa.

Concurrently, the growth of national strategic biodefense stockpiles serves as a fundamental stabilizer, providing long-term sustainability for pharmaceutical developers. Governments regard smallpox as a severe biological weapon threat, requiring maintained reserves of second-generation vaccines and antivirals irrespective of current infection levels. This security-focused approach results in multi-year contracts that protect companies from commercial volatility, as seen when SIGA Technologies announced in July 2024 that the U.S. Department of Health and Human Services exercised a $113 million procurement option for oral TPOXX. Furthermore, Emergent BioSolutions reported in July 2024 that it secured a $99.9 million contract modification to continue supplying the ACAM2000 vaccine to the U.S. Strategic National Stockpile, underscoring the sector's dependence on federal defense spending.

Market Challenge

The dependence on irregular government contracts acts as a major restraint on the global smallpox treatment market, generating a volatile revenue landscape that discourages steady private sector investment. In contrast to commercial pharmaceutical areas driven by consistent patient needs, this market relies heavily on biodefense stockpiling mandates and sporadic procurement cycles. Manufacturers must sustain costly, specialized production capabilities and regulatory readiness without the assurance of recurring sales, creating a boom-and-bust dynamic where income can disappear suddenly if threats are perceived to diminish or public health priorities change, thereby complicating long-term strategic planning.

This instability is worsened by the conditional nature of procurement, which frequently occurs only during active emergencies rather than through consistent preventative funding. This reactive model forces companies to bear the risks associated with capacity maintenance and inventory management. For example, UNICEF launched an emergency tender in 2024 to potentially acquire up to 12 million mpox vaccine doses through 2025, yet the acquisition was explicitly dependent on confirmed demand and available financing. This case illustrates how the reliance on unsecured public funding and the absence of a guaranteed commercial consumer base impede the market's capacity to sustain a stable growth trajectory.

Market Trends

Manufacturers and regulatory bodies are renewing their focus on extending drug labels to include special risk groups and pediatric populations, addressing a significant gap in historical biodefense strategies that previously excluded these demographics. This trend involves increasing regulatory actions and clinical trials specifically aimed at children to ensure broad protection against orthopoxviruses, pivoting toward the deployment of safer, third-generation vaccines that induce immunity in younger subjects without the severe side effects of earlier formulations. In a key development, the World Health Organization reported in November 2024 that it granted emergency approval for the LC16m8 vaccine for children over one year old and facilitated the donation of 3.05 million doses from Japan to the Democratic Republic of the Congo to safeguard this vulnerable group.

Biopharmaceutical firms are increasingly combining their research and development pipelines for mpox and smallpox, using active outbreaks to validate dual-indication therapeutics. By leveraging clinical data from mpox cases, developers can expedite regulatory approval pathways for broad-spectrum orthopoxvirus countermeasures that would otherwise be challenging to test due to the eradication of smallpox. This strategic consolidation optimizes R&D expenditure and ensures new platforms, such as mRNA technology, can quickly address emerging threats while fulfilling long-term government biodefense obligations, as demonstrated by Moderna's advancement of a Phase 1/2 clinical trial for its mRNA-1769 candidate against both viruses, reported by Pharmaceutical Technology in September 2024.

Key Market Players

• Bavarian Nordic A/S
• Chimerix, Inc.
• Pfizer Inc.
• Sanofi SA
• GlaxoSmithKline plc
• Novartis AG
• Johnson & Johnson
• SIGA Technologies, Inc.
• BioCryst Pharmaceuticals, Inc.
• Bharat Biotech International Ltd

Report Scope

In this report, the Global Smallpox Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Smallpox Treatment Market, By Treatment Type

• Antiviral Drugs
• Vaccination
• Supportive Care

Smallpox Treatment Market, By Product Type

• Vaccines
• Antiviral Drugs

Smallpox Treatment Market, By End user

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Smallpox Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Smallpox Treatment Market.

Available Customizations:

Global Smallpox Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Smallpox Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment Type (Antiviral Drugs, Vaccination, Supportive Care)
  • 5.2.2. By Product Type (Vaccines, Antiviral Drugs)
  • 5.2.3. By End user (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Smallpox Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment Type
  • 6.2.2. By Product Type
  • 6.2.3. By End user
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Smallpox Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment Type
      • 6.3.1.2.2. By Product Type
      • 6.3.1.2.3. By End user
  • 6.3.2. Canada Smallpox Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment Type
      • 6.3.2.2.2. By Product Type
      • 6.3.2.2.3. By End user
  • 6.3.3. Mexico Smallpox Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment Type
      • 6.3.3.2.2. By Product Type
      • 6.3.3.2.3. By End user

7. Europe Smallpox Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment Type
  • 7.2.2. By Product Type
  • 7.2.3. By End user
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Smallpox Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment Type
      • 7.3.1.2.2. By Product Type
      • 7.3.1.2.3. By End user
  • 7.3.2. France Smallpox Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment Type
      • 7.3.2.2.2. By Product Type
      • 7.3.2.2.3. By End user
  • 7.3.3. United Kingdom Smallpox Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment Type
      • 7.3.3.2.2. By Product Type
      • 7.3.3.2.3. By End user
  • 7.3.4. Italy Smallpox Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment Type
      • 7.3.4.2.2. By Product Type
      • 7.3.4.2.3. By End user
  • 7.3.5. Spain Smallpox Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment Type
      • 7.3.5.2.2. By Product Type
      • 7.3.5.2.3. By End user

8. Asia Pacific Smallpox Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment Type
  • 8.2.2. By Product Type
  • 8.2.3. By End user
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Smallpox Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment Type
      • 8.3.1.2.2. By Product Type
      • 8.3.1.2.3. By End user
  • 8.3.2. India Smallpox Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment Type
      • 8.3.2.2.2. By Product Type
      • 8.3.2.2.3. By End user
  • 8.3.3. Japan Smallpox Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment Type
      • 8.3.3.2.2. By Product Type
      • 8.3.3.2.3. By End user
  • 8.3.4. South Korea Smallpox Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment Type
      • 8.3.4.2.2. By Product Type
      • 8.3.4.2.3. By End user
  • 8.3.5. Australia Smallpox Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment Type
      • 8.3.5.2.2. By Product Type
      • 8.3.5.2.3. By End user

9. Middle East & Africa Smallpox Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment Type
  • 9.2.2. By Product Type
  • 9.2.3. By End user
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Smallpox Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment Type
      • 9.3.1.2.2. By Product Type
      • 9.3.1.2.3. By End user
  • 9.3.2. UAE Smallpox Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment Type
      • 9.3.2.2.2. By Product Type
      • 9.3.2.2.3. By End user
  • 9.3.3. South Africa Smallpox Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment Type
      • 9.3.3.2.2. By Product Type
      • 9.3.3.2.3. By End user

10. South America Smallpox Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment Type
  • 10.2.2. By Product Type
  • 10.2.3. By End user
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Smallpox Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment Type
      • 10.3.1.2.2. By Product Type
      • 10.3.1.2.3. By End user
  • 10.3.2. Colombia Smallpox Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment Type
      • 10.3.2.2.2. By Product Type
      • 10.3.2.2.3. By End user
  • 10.3.3. Argentina Smallpox Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment Type
      • 10.3.3.2.2. By Product Type
      • 10.3.3.2.3. By End user

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Smallpox Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Bavarian Nordic A/S
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Chimerix, Inc.
• 15.3. Pfizer Inc.
• 15.4. Sanofi SA
• 15.5. GlaxoSmithKline plc
• 15.6. Novartis AG
• 15.7. Johnson & Johnson
• 15.8. SIGA Technologies, Inc.
• 15.9. BioCryst Pharmaceuticals, Inc.
• 15.10. Bharat Biotech International Ltd

16. Strategic Recommendations

17. About Us & Disclaimer